IN2012DN01254A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01254A
IN2012DN01254A IN1254DEN2012A IN2012DN01254A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A IN 1254DEN2012 A IN1254DEN2012 A IN 1254DEN2012A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A
Authority
IN
India
Prior art keywords
compounds
enteralor
ainfections
isozazole
substituents
Prior art date
Application number
Other languages
English (en)
Inventor
Yitsun Richard Kao
Dan Yang
Kwokyung Yuen
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of IN2012DN01254A publication Critical patent/IN2012DN01254A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN1254DEN2012 2009-08-05 2010-08-05 IN2012DN01254A (enEXAMPLES)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23143109P 2009-08-05 2009-08-05
PCT/CN2010/001187 WO2011015037A1 (en) 2009-08-05 2010-08-05 Antiviral compounds and methods of making and using there of cross reference to related applications

Publications (1)

Publication Number Publication Date
IN2012DN01254A true IN2012DN01254A (enEXAMPLES) 2015-05-15

Family

ID=43543887

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1254DEN2012 IN2012DN01254A (enEXAMPLES) 2009-08-05 2010-08-05

Country Status (13)

Country Link
EP (1) EP2462138B1 (enEXAMPLES)
JP (1) JP2013501008A (enEXAMPLES)
KR (1) KR20120092567A (enEXAMPLES)
CN (1) CN102596946B (enEXAMPLES)
AU (1) AU2010281265A1 (enEXAMPLES)
BR (1) BR112012002331A2 (enEXAMPLES)
CA (1) CA2770140A1 (enEXAMPLES)
IL (1) IL217745A0 (enEXAMPLES)
IN (1) IN2012DN01254A (enEXAMPLES)
MX (1) MX2012001504A (enEXAMPLES)
RU (1) RU2012104214A (enEXAMPLES)
SG (1) SG178106A1 (enEXAMPLES)
WO (1) WO2011015037A1 (enEXAMPLES)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011147198A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
ES2533068T3 (es) * 2010-09-08 2015-04-07 Bristol-Myers Squibb Company Nuevos análogos de piperazina como antivirales de influenza de amplio espectro
EA201390476A1 (ru) * 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US20140011700A1 (en) * 2011-03-25 2014-01-09 Bristol-Myers Squibb Company Three-dimensional structure of h1n1 nucleoprotein in complex with antiviral compounds
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
CN102432555A (zh) * 2011-09-09 2012-05-02 中国科学院广州生物医药与健康研究院 1,2,3-三氮唑-4(5)羧酰胺类化合物及其应用
KR20140141596A (ko) 2012-03-13 2014-12-10 레스피버트 리미티드 결정질 pi3 키나아제 저해제
AU2013261735B2 (en) 2012-05-18 2017-07-20 Vironova Influenza Ab Methanethione compounds having antiviral activity
US9676734B2 (en) 2012-05-18 2017-06-13 Vironova Influenza Ab Compounds and methods
ES2832497T3 (es) 2012-06-13 2021-06-10 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9227977B2 (en) 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
JP6397912B2 (ja) * 2013-07-30 2018-09-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Rsv抗ウイルス化合物としての置換ピリジンピペラジニルアナログ
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
AU2018216954B2 (en) * 2017-02-02 2022-04-14 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションIncyte Corporation Fgfr阻害剤の固体形態及びその調製プロセス
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019301944B2 (en) 2018-07-10 2022-02-24 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
MA54758A (fr) 2019-01-18 2022-04-27 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI765323B (zh) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 抗流感病毒化合物及其製備方法和用途
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021204924A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Compounds for use in the treatment of hypercytokinemia
WO2021204923A1 (en) 2020-04-09 2021-10-14 Vironova Medical Ab Antiviral agents
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
ES3028915T3 (en) 2021-04-16 2025-06-20 Gilead Sciences Inc Methods of preparing carbanucleosides using amides
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117150A (ja) * 1991-10-25 1993-05-14 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
KR200293242Y1 (ko) * 2002-04-18 2002-11-01 전이범 산소 절단기호스
DE10236564A1 (de) * 2002-08-08 2004-05-19 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von papaverinartigem Vasodilatator und pharmazeutische Zusammensetzung
WO2006089177A2 (en) * 2005-02-17 2006-08-24 Synta Pharmaceuticals Corp. Isoxazole combretastin derivatives for the treatment of disorders
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
EP2462138B1 (en) 2014-09-24
CN102596946B (zh) 2015-06-17
MX2012001504A (es) 2012-06-01
AU2010281265A2 (en) 2012-04-05
IL217745A0 (en) 2012-03-29
JP2013501008A (ja) 2013-01-10
CN102596946A (zh) 2012-07-18
CA2770140A1 (en) 2011-02-10
KR20120092567A (ko) 2012-08-21
SG178106A1 (en) 2012-03-29
EP2462138A4 (en) 2013-01-23
BR112012002331A2 (pt) 2019-09-24
AU2010281265A1 (en) 2012-03-22
WO2011015037A1 (en) 2011-02-10
RU2012104214A (ru) 2013-09-10
EP2462138A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
IN2012DN01254A (enEXAMPLES)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PE20160127A1 (es) COMPUESTO ACIDO (2S,3S)-3-((2-(5-FLUORO-1H-PIRROLO[2,3-B]PIRIDIN-3-IL)-5-FLUOROPIRIMIDIN-4-IL)AMINO)BICICLO[2.2.2]OCTANO-2-CARBOXILICO COMO INHIBIDOR DE LA REPLICACION DEL VIRUS DE LA GRIPE A H1N1, H2N2, H3N2 o H5N1
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
MX2013007104A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MX371093B (es) Compuestos de microarn y metodos para modular al mir-122.
BR112015013463A8 (pt) Derivados de carboxamida indol como antagonistas do receptor de p2x7
IL321503A (en) Recombinant virus, composition comprising the same, and uses thereof
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
BR112014017735A8 (pt) Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201190234A1 (ru) Новые амидные производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
EA201190236A1 (ru) Новые производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
SG194711A1 (en) Processes for preparing inhibitors of the hepatitis c virus
ECSP13013080A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
IN2011CH03893A (enEXAMPLES)
EA201370058A1 (ru) Средство против вируса гриппа b